Pathogenesis of Cardiotoxicity Induced by Anthracyclines

Seminars in Oncology

Volumn 33, Issue SUPPL. 8, 2006, Pages 2-7

  Elliott, Perry ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BLEOMYCIN; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; CYCLOPHOSPHAMIDE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; EPIRUBICIN; FREE RADICAL; IRON; PREDNISONE; TROPONIN; VINCRISTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE HEART INFARCTION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DISEASE COURSE; DRUG FATALITY; ECG ABNORMALITY; GROUPS BY AGE; HEART ATRIUM ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART INJURY; HEART VENTRICLE EXTRASYSTOLE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LONG TERM CARE; NONHODGKIN LYMPHOMA; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SIDE EFFECT; SINUS TACHYCARDIA; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; RISK FACTORS;

EID: 33745008604     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.04.020     Document Type: Article

References (34)

1. Orditura M., Quaglia F., Morgillo F., et al. Pegylated liposomal doxorubicin. Pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review). Oncol Rep 12 (2004) 549-556
2. Minotti G., Menna P., Salvatorelli E., et al. Anthracyclines. Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56 (2004) 185-229
3. Andrieu-Abadie N. [Cardiotoxicity of anthracyclines. mechanisms and pharmacologic targets for prevention]. Therapie 59 (2004) 121-126
4. Tan C., Tasaka H., Yu K.P., et al. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 20 (1967) 333-353
5. Swain S.M., Whaley F.S., and Ewer M.S. Congestive heart failure in patients treated with doxorubicin. A retrospective analysis of three trials. Cancer 97 (2003) 2869-2879
6. Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91 (1979) 710-717
7. Stevenson L.W. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail 1 (1999) 251-257
8. Jensen B.V., Skovsgaard T., and Nielsen S.L. Functional monitoring of anthracycline cardiotoxicity. A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13 (2002) 699-709
9. Catimel G., Spielmann M., Dieras V., et al. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer. A preliminary report on safety. Semin Oncol 23 suppl 1 (1996) 24-27
10. Limat S., Demesmay K., Voillat L., et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 14 (2003) 277-281
11. Ryberg M., Nielsen D., Skovsgaard T., et al. Epirubicin cardiotoxicity. An analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16 (1998) 3502-3508
12. Haq M.M., Legha S.S., Choksi J., et al. Doxorubicin-induced congestive heart failure in adults. Cancer 56 (1985) 1361-1365
13. Krischer J.P., Epstein S., Cuthbertson D.D., et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer. The Pediatric Oncology Group experience. J Clin Oncol 15 (1997) 1544-1552
14. Lipshultz S.E., Colan S.D., Gelber R.D., et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324 (1991) 808-815
15. Shan K., Lincoff A.M., and Young J.B. Anthracycline-induced cardiotoxicity. Ann Intern Med 125 (1996) 47-58
16. Lipshultz S.E., Lipsitz S.R., Sallan S.E., et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23 (2005) 2629-2636
17. Zambetti M., Moliterni A., Materazzo C., et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 19 (2001) 37-43
18. Meinardi M.T., van Veldhuisen D.J., Gietema J.A., et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19 (2001) 2746-2753
19. Praga C., Beretta G., Vigo P.L., et al. Adriamycin cardiotoxicity. A survey of 1273 patients. Cancer Treat Rep 63 (1979) 827-834
20. Li T., and Singal P.K. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 102 (2000) 2105-2110
21. Arola O.J., Saraste A., Pulkki K., et al. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 60 (2000) 1789-1792
22. Childs A.C., Phaneuf S.L., Dirks A.J., et al. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 62 (2002) 4592-4598
23. Kremer L.C., van Dalen E.C., Offringa M., et al. Anthracycline-induced clinical heart failure in a cohort of 607 children. Long-term follow-up study. J Clin Oncol 19 (2001) 191-196
24. Steinherz L.J., Steinherz P.G., Tan C.T., et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266 (1991) 1672-1677
25. Haddy T.B., Adde M.A., McCalla J., et al. Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas. J Clin Oncol 16 (1998) 2070-2079
26. Ewer M.S., Ali M.K., Mackay B., et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol 2 (1984) 112-117
27. Larsen R.L., Jakacki R.I., Vetter V.L., et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 70 (1992) 73-77
28. Billingham M.E., Mason J.W., Bristow M.R., et al. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62 (1978) 865-872
29. Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur Heart J 25 (2004) 1187-1196
30. Antman E.M. Decision making with cardiac troponin tests. N Engl J Med 346 (2002) 2079-2082
31. Cardinale D., Sandri M.T., Martinoni A., et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 13 (2002) 710-715
32. Auner H.W., Tinchon C., Linkesch W., et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 82 (2003) 218-222
33. Lipshultz S.E., Rifai N., Sallan S.E., et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96 (1997) 2641-2648
34. Thomas X., Le Q.H., and Fiere D. Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia. Ann Hematol 81 (2002) 504-507